Driver Mutationen als therapeutisches Konzept – die CML als Paradigma

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Assoz. Prof. Dr. Karoline V. Gleixner

Abt. für Hämatologie und Hämostaseologie, Klinik für Innere Medizin I Medizinische Universität Wien


  1. Hehlmann R et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32:415-423
  2. Castagnetti F et al. GIMEMA CML Working Party. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia 2015; 29:1823-1831
  3. Nowell PC et al. A minute chromosome in human granulocytic leukemia. Science 1960; 132
  4. Heisterkamp N et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983; 306
  5. Chereda B et al. Natural course and biology of CML. Ann Hematol 2015; 94
  6. Druker BJ et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2(5):561-566
  7. O’Brien SG et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004
  8. Giles FJ, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013; 27:107-112
  9. Shah NP et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 2014; 123:2317-2324
  10. Smith B et al. Efficacy of bosutinib in imatinib-resistant vs dasatinib/nilotinib-resistant chronic phase chronic myeloid leukemia: results from the Phase 4 BYOND Study. Blood 2019; 134:1650
  11. Hochhaus A et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34(4):966-984
  12. Cortes JE et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369:1783-1796
  13. Shah NP et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117-125
  14. Quintás-Cardama A et al. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008; 14(14):4392-4399
  15. Hochhaus A et al. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia 2020; 34(6):1495-1502
  16. Hochhaus A et al. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 2007; 44(S1):S15-S24
  17. Loscocco F et al. BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia. Front Oncol 2019; 9:939
  18. Milojkovic D et al. Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica 2012; 97(3):473-474
  19. Schneeweiss-Gleixner M et al. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML. EBioMedicine 2019; 50:111-121
  20. Gratwohl A et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia 2016; 30(3):562-569
  21. Khorashad JS et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013; 121(3):489-498
  22. Valent P et al. Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. Leuk Lymphoma 2008; 49(4):604-609
  23. Claudiani S et al. The argument for using imatinib in CML. Hematology Am Soc Hematol Educ Program 2018; 2018(1):161-167
  24. Cross NC et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015; 29:999-1003
  25. Etienne G et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol 2017; 35(3):298-305
  26. Campiotti L et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. Eur J Cancer 2017; 77:48-56

SO 06|2020

Herausgeber: Univ.-Prof. Dr. Matthias Preusser, Univ.-Prof. Dr. Markus Raderer
Publikationsdatum: 2020-10-27